These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25162897)

  • 1. Evolocumab in hyperlipidemia.
    Meyer RJ
    N Engl J Med; 2014 Aug; 371(9):876. PubMed ID: 25162897
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolocumab in hyperlipidemia.
    Tomoda H
    N Engl J Med; 2014 Aug; 371(9):876-7. PubMed ID: 25162898
    [No Abstract]   [Full Text] [Related]  

  • 3. Evolocumab in hyperlipidemia.
    Blom DJ; Wasserman SM; Stein EA
    N Engl J Med; 2014 Aug; 371(9):877-8. PubMed ID: 25162896
    [No Abstract]   [Full Text] [Related]  

  • 4. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
    Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
    N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperlipidemia. New treatment option with Evolocumab].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 2014 Jul; 37(7):271-2. PubMed ID: 25065173
    [No Abstract]   [Full Text] [Related]  

  • 6. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolocumab: A Review in Hyperlipidemia.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Strategies to Treat High Cholesterol.
    Blum CB; Stone NJ
    JAMA; 2016 Mar; 315(11):1169. PubMed ID: 26978218
    [No Abstract]   [Full Text] [Related]  

  • 10. New Strategies to Treat High Cholesterol--Reply.
    Shrank WH; Barlow J
    JAMA; 2016 Mar; 315(11):1169-70. PubMed ID: 26978219
    [No Abstract]   [Full Text] [Related]  

  • 11. Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):140-1. PubMed ID: 26445204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolocumab (AMG 145) for primary hypercholesterolemia.
    Langslet G; Emery M; Wasserman SM
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.
    Roth EM; Diller P
    Future Cardiol; 2014 Mar; 10(2):183-99. PubMed ID: 24762246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [First PCSK9 inhibitor].
    Westphal K
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27462666
    [No Abstract]   [Full Text] [Related]  

  • 15. [First PCSK9 inhibitor].
    Westphal K
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324017
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effective LDL cholesterol reduction for high risk patients].
    Einecke D
    MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
    [No Abstract]   [Full Text] [Related]  

  • 17. Alirocumab (Praluent) to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
    [No Abstract]   [Full Text] [Related]  

  • 18. [2nd PCSK9 inhibitor for effective LDL decrease].
    Einecke D
    MMW Fortschr Med; 2016 Feb; 158(2):65. PubMed ID: 26961048
    [No Abstract]   [Full Text] [Related]  

  • 19. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.
    Shrank WH; Barlow JF; Brennan TA
    JAMA; 2015 Oct; 314(14):1443-4. PubMed ID: 26258765
    [No Abstract]   [Full Text] [Related]  

  • 20. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
    Schulman KA; Balu S; Reed SD
    N Engl J Med; 2015 Oct; 373(17):1591-3. PubMed ID: 26444460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.